



**THE TRENDLINES GROUP LTD.**

(Incorporated in Israel)

(Company Registration No. 513970947)

---

**Questions and Answers Provided by the Trendlines Group Ahead of Upcoming Annual General Meeting and Special General Meeting**

---

The Board of Directors of The Trendlines Group Ltd. (“**Trendlines**” or the “**Company**” and together with its subsidiaries, the “**Group**”) wishes to address questions received from shareholders prior to the upcoming annual general meeting for its financial year ended 31 December 2023 (“**AGM**”) and the special general meeting (“**SGM**”) to be held on 18 April 2024. It is customary for shareholders to utilize an AGM and SGM to direct questions to the Company with respect to its recently published Annual Report 2023 or regarding the resolutions to be presented at meetings such as our AGM and the SGM.

**1. Based on your strategic plan announced in Nov 22, what outcome can we reasonably expect in FY2024?**

As we communicated in our Annual Report for FY2023, we are focusing our efforts wholly on our maturing portfolio companies with a view to bringing as many to exit as possible in the coming years. Concurrently, the Company has made organizational and structural changes to focus on our core business, while reducing operating costs. We believe that these changes steer our business to enable us to reach better results in 2024.

**2. Since the IPO in 2015, the share price has been languishing with no respite irrespective of results. What is management doing to boost share price or enhance the company's profile and image?**

The Company shares our shareholders’ disappointment regarding the share price. We hope that with improved results, we will be able to bolster our image and rebuild the faith in our Company.

**3. The Company’s practice of announcing standard monthly report may be transparent but is monotonous and unexciting. Perhaps management should follow what most SGX company practice of announcing contract win or big news (such as FDA clearance of product) in a piece-meal basis. This would generate excitement just like what pharmaceutical company do in the USA.**

In addition to our monthly updates, we constantly update our news page with investment rounds, FDA clearance notifications, collaboration agreements, and any noteworthy milestones achieved by our portfolio companies. These items are published in our monthly update and in our Trendletter, as well as on all our social media platforms. The monthly update serves as a collection of these news items.

**4. On page 8 of your company report, how do you derive the fair value of Trendlines' share on the various sections? And also, the Non-IFRS fair value as well?**

All of our portfolio companies are evaluated annually by a professional independent valuation company. Please refer to page 9 of the Annual Report of the Company which describes in the Notes and the Disclaimer about the parameters used to establish the Non-IFRS fair values.

BY ORDER OF THE BOARD

Haim Brosh

Chief Executive Officer and Interim Chief Financial Officer

11 April 2024

--- End ----

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.*